Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.47 |
| ▸ | THRB | P10828 | 5/20 | 0.42 |
| ▸ | THRA | P10827 | 4/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883861 | 0.80 | PTGDR2 (0.56) | PTGDR2PTGDR | |
| SCHEMBL4638347 | 0.78 | AR (0.41) | DDR1 | |
| SCHEMBL2065914 | 0.74 | PTGDR2 (0.49) | PTGDR2PTGDR | |
| SCHEMBL2394982 | 0.73 | PTGDR2 (0.44) | PTGDR2DDR1RHEB | |
| SCHEMBL2065273 | 0.72 | SCN9A (0.43) | PTGDR2THRBTHRAPTGDRSMN1; SMN2 | |
| SCHEMBL2066732 | 0.72 | PTGDR2 (0.53) | PTGDR2PTGDR | |
| SCHEMBL2065821 | 0.71 | PTGDR2 (0.47) | PTGDR2THRBTHRA | |
| SCHEMBL4877093 | 0.71 | DDR1 (0.48) | PTGDR2DDR1RHEB | |
| SCHEMBL2065952 | 0.71 | PTGDR2 (0.55) | PTGDR2PTGDR | |
| SCHEMBL2065895 | 0.71 | PTGDR2 (0.50) | PTGDR2THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | claimed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148572-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| WO-2007039736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192163-A1 | Novel Compounds | PAH, PC, DDC | PTGDR2 1000/4885THRB 2307/4885THRA 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.